Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.

ABSTRACT:

Introduction

Antitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas. This study aims to determine which anti-glioma medication presents the lowest risk for personalized use in clinical patients by assessing the adverse drug reactions (ADRs) associated with these medications as reported in the World Health Organization (WHO) VigiAcess database, and by comparing the characteristics of adverse responses among the three drugs.

Methods

This investigation employs a retrospective descriptive analysis method. We compiled ADR reports for three commercially available anti-glioma medications from WHO-VigiAccess, gathering d

SUBMITTER: Ke H 

PROVIDER: S-EPMC11540626 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature